-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $44

Benzinga·02/25/2026 09:29:24
Listen to the news
Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $46 to $44.